E3353_06 [ALT4ax].png
master-logo-black-text_7a.png
EtcemblyTCRs-circles_5a.png
Accelerate
the pathway to
clinical trials with 
our revolutionary
machine learning
platform
EtcemblyTCRs-circles_5a.png
Gain the
upper hand in
the evolutionary
arms race between
humans and pathogens
EtcemblyTCRs-circles_5a.png
DEMYSTIFY
T CELL RECEPTORS
& UNLOCK A NEW
WORLD OF IMMUNE
THERAPIES
 

ABOUT

 

T Cell Receptors (TCRs) constitute one of the most promising classes of emerging therapeutics. Whilst TCRs are amongst the most complex facets of immune biology, engineering of an optimum T Cell Receptor can transform immunotherapies and personalised medicines. 

Etcembly is building the world’s largest machine learning database and unmatched immunology expertise to deliver the safest and most powerful TCR immunotherapies through rapid computer-assisted engineering.

Etcembly_BRAIN_2b.png

PEPTIDE 

HEMISPHERE

SUCCESSFUL

IMMUNOTHERAPY RELIES

ON UNDERSTANDING

TWO HEMISPHERES

TCR 

HEMISPHERE

 

APPROACHING THE CHALLENGE

 

The TCR repertoire at any time point reflects on the person’s health and contains a memory of all past experiences. However, TCRs are highly variable and their activities aren’t easily predictable with traditional empirical methods.  

 

Data on a new TCR candidate should not only validate affinity, but also deliver exhaustive confirmation of every possibility of off-target, cross-reactive, or toxicity binding events.

 

By understanding an increasing database of TCR repertoires, Etcembly will be able to develop tools to assess immune health and identify disease biomarkers.

 

Our AI platform learns from the pattern of T cell target interactions and identifies T Cell Receptors that can be used to treat specific diseases in the clinic.

 
E3353_06 [ALT4bxx].png

Etcembly has developed a proprietary machine learning platform - EMLy™ - trained and optimised to find deeply complex patterns in TCR repertoires. By leveraging this diversity, our AI, governed by biophysics, validated and optimised through empirical results, will lead to effective design of personalised therapeutics.

 

By employing our three-faceted TCR discovery platform, engineered to compress timelines and deliver rapid unbiased insights, your immune-based therapy will have the highest chance of success in specificity and efficacy in the quickest time possible.

INTRODUCING

EMLy-type_dark-grey_1.png
EtcemblyTCRs-circles_5b.png
Design
safe and potent
TCRs for the clinic
EtcemblyTCRs-circles_5a.png
Optimise 
TCR therapies
EtcemblyTCRs-circles_5b.png
Create
diagnostics that identify the
right patient population
EtcemblyTCRs-circles_5a.png
Determine
how the immune system is driven by external factors
such as ethnicity
and age
EtcemblyTCRs-circles_5a.png
Design
personalised therapeutics
across all patient groups
 

THREE PILLARS TO SUCCESS

 

1:  A well-trained, highly specific Machine Learning platform will explore the entire universe of possibilities, quickly identifying the highest potential TCR candidates that have the highest affinity and lowest probability of cross-reactivity, off-target or toxicity events.

 

2.  Data-guided empirical optimisation cycles and engineering will rapidly develop ideal TCR candidate(s) and eliminate adverse effects.

 

3. Rigorous in vitro validation will provide the predictive confidence that the ideal TCR candidate is clinically safe and potent.

 

Data extraction on public domains

EtcemblyPlatform_1g.png

TCR OPTIMISATION

 

Neural networks

 

TCR candidates

Structural analysis of pHLA:TCR

Affinity measurement

Functional readout

Off-target
toxicity

 

DEEP NEURAL ARCHITECTURE

INTEGRATED WITH THE DATABASE

form the basis of EMLy’s computation in novel

diagnostic and theraputic solutions.

Deep sequencing
of patient derived
T cells (public domain and proprietry)

EtcemblyPlatform_2g.png

TCR Sequencing data (public domain and proprietry)

 

 

3D structural modelling

Profile biomarkers for treatment selection and outcome prediction

Novel and
optimised T cell and neoantigen-directed immunotherapies

Personalised immunotherapy design

 
Etcembly_Dots-PAttern_1d.png

BENEFITS

EtcemblyTCRs-circles_5b.png
Aids
insurance
company
assessment
EtcemblyTCRs-circles_5a.png
Helps
Healthcare
systems
EtcemblyTCRs-circles_5a.png
Lean drug
discovery for pharma
EtcemblyTCRs-circles_5a.png
Swift
pathway 
to clinical
trials
 

OUR TEAM

E3353_06 [ALT5d].png
Etcembly_Dots-PAttern_1c.png
Etcembly_Dots-PAttern_1c.png
Nick Pumphrey 5Jun2022-thumbnail3.png

Nick Pumphrey

CSO

 

Over 20 years' experience developing TCR-based therapeutics at Immunocore and Adaptimmune

Etcembly_Dots-PAttern_1c.png
NickC 2.png

Nick Cross

Chairman

 

Serial entrepreneur and investor.

Etcembly_Dots-PAttern_1c.png
Etcembly_Dots-PAttern_1c.png
Etcembly_Dots-PAttern_1c.png
Scott_0379.png

Scott Cuthill

CBO

 

Pharma veteran. Held senior BD roles at Chroma Therapeutics, Ipsen and ValoTx

Etcembly_Dots-PAttern_1c.png
BentJakobsen4.png

Bent Jakobsen

Director

 

CEO of Accession Therapeutics

Founded Immunocore and Adaptimmune  

Etcembly_Dots-PAttern_1c.png
Leon Toh 3.jpg

Leon Toh

VP Operations (Asia Pacific)

 

Impact investment, founder of Damson Ventures

JacobH2.png

Jacob Hurst

CTO Co-founder

 

25 years of bioinformatics experience spanning across translational medicine, HIV, TCR and antibody repertoire analytics 

MichellT2.png

Michelle Teng

CEO Co-founder

20 years of R&D experience working on a breadth of projects from lead discovery to translational medicine.

JohmM 3.png

John McCafferty

Scientific Advisor

 

Serial entrepreneur. Founder of Cambridge Antibody Technology, Maxion Tx and IonTas

E3353_06 [ALT5c].png

PARTNERS

Contact

If you are as excited about our journey as 

we are, then please drop us an email.

 

 

Careers

We are committed to developing the next generation of scientists and welcome motivated individuals who share our vision. If you aspire to break boundaries in precision medicine and are able to demonstrate understanding in the convergence of these fields, we are interested in hearing from you.

Get in touch here

hello@etcembly.com

Illumina Logo.png
GOS Hosp logo.png
Zelluna Logo.png
NCC Singapore.png
Imperial College logo.png
 
 
 
Etcembly_Dots-PAttern_1d.png